{"pub": "financialpost", "url": "https://globenewswire.com/news-release/2019/10/24/1935383/0/en/Profound-Medical-to-Release-Third-Quarter-2019-Financial-Results-on-November-7-Conference-Call-to-Follow.html", "downloaded_at": "2019-10-24 23:48:28.490701+00:00", "title": "Profound Medical to Release Third Quarter 2019 Financial Results on November 7 \u2013 Conference Call to Follow", "language": "en", "text": "TORONTO, Oct. 24, 2019 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; OTCQX:PRMFD) (\u201cProfound\u201d or the \u201cCompany\u201d), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (\u201cMRI\u201d), thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue, will announce its third quarter 2019 financial results after market close on Thursday, November 7, 2019.\n\n\n\nProfound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period.\n\nThird Quarter 2019 Results Conference Call Details:\n\nDate: Thursday, November 7, 2019 Time: 4:30 p.m. ET Live Call: 1-877-407-9210 (Canada and the United States) 1-201-689-8049 (International) Replay: 1-919-882-2331 Replay ID: 55908\n\nThe call will also be broadcast live and archived on the Company's website at www.profoundmedical.com under \"Webcasts\" in the Investors section.\n\nAbout Profound Medical Corp.\n\nProfound develops and markets customizable, incision-free therapies for the ablation of diseased tissue.\n\nProfound is commercializing TULSA-PRO\u00ae, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO\u00ae is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while actively protecting the urethra and rectum to help preserve the patient\u2019s natural functional abilities. We believe TULSA-PRO\u00ae is demonstrating to be a flexible technology in customizable prostate ablation, including intermediate stage cancer, localized radio-recurrent cancer, retention and hematuria palliation in locally advanced prostate cancer, and the transition zone in large volume benign prostatic hyperplasia (BPH). TULSA-PRO\u00ae is CE marked and received 510(k) clearance from the U.S. Food and Drug Administration in August 2019.\n\nProfound is also commercializing Sonalleve\u00ae, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. Sonalleve\u00ae has also been approved by the China Food and Drug Administration for the non-invasive treatment of uterine fibroids. The Company is in the early stages of exploring additional potential treatment markets for Sonalleve\u00ae where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.\n\nForward-Looking Statements\n\nThis news release includes forward-looking statements regarding Profound and its business which may include, but are not limited to, statements with respect to the efficacy of its technology in the treatment of prostate cancer, uterine fibroids and palliative pain treatment. Often, but not always, forward-looking statements can be identified by the use of words such as \u201cplans\u201d, \u201cis expected\u201d, \u201cexpects\u201d, \u201cscheduled\u201d, \u201cintends\u201d, \u201ccontemplates\u201d, \u201canticipates\u201d, \u201cbelieves\u201d, \u201cproposes\u201d or variations (including negative variations) of such words and phrases, or state that certain actions, events or results \u201cmay\u201d, \u201ccould\u201d, \u201cwould\u201d, \u201cmight\u201d or \u201cwill\u201d be taken, occur or be achieved. Such statements are based on the current expectations of the management of Profound. The forward-looking events and circumstances discussed in this release, may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including risks the pharmaceutical industry, economic factors, the equity markets generally and risks associated with growth and competition. Although Profound has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Profound undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, other than as required by law.\n\nFor further information, please contact:", "description": "", "authors": ["Profound Medical Inc.", "Profound Medical Corp."], "top_image": "http://www.globenewswire.com/Attachment/LogoDisplay/818441?filename=818441.jpg&size=1", "published_at": "2019-10-24"}